UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2026

Commission File Number: **001-42128**

Telix Pharmaceuticals Limited

(Translation of registrant's name into English)

55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On March 10, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed announcements with the Australian Securities Exchange titled "ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives," a copy of which is attached to this Form 6-K as Exhibit 99.1, and "ProstACT Global Phase 3 (Part 1) Results Presentation," a copy of which is attached to this Form 6-K as Exhibit 99.2.

The information contained in this Form 6-K, except for the commentary within Exhibit 99.1 appearing in the last paragraph on page 1 and the first paragraph on page 2, is incorporated by reference into our Registration Statement on Form F-3ASR (File No. 333-293611) and Registration Statement on Form S-8 (File No. 333-283917).

99.1	Press release – March 10, 2026
99.2	Presentation – March 10, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Telix Pharmaceuticals Limited

Date: March 10, 2026

By: /s/ Genevieve Ryan

Name: Genevieve Ryan
Title: Company Secretary

Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

- Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html

Melbourne (Australia) and Indianapolis, IN (U.S.) – March 10, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (^{177}Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.

Key findings include:

- Tolerability profile supported by dosimetry and low-grade non-hematologic events.
- Lesion dosimetry indicates no difference in absorbed dose profile across cohorts.
- No adverse drug-drug interactions observed in TLX591-Tx combinations.
- Hematologic events are in line with expectations and transient and manageable, with similar rates of recovery across all patient cohorts.
- The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

Part 1 of the study confirmed the safety profile, biodistribution and dosimetry of TLX591-Tx administered in two doses, 14 days apart, in combination with one of three standard of care (SOC) therapies: abiraterone, enzalutamide or docetaxel. The patient population comprised prostate-specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) patients previously treated with one androgen receptor pathway inhibitor (ARPI).

ProstACT Global is a differentiated Phase 3 trial comparing PSMA-targeted ^{177}Lu-rADC therapy administered with SOC versus SOC alone, a trial design intended to reflect current global clinical practice[1]. Telix has already advanced the study into Part 2 – a 2:1 randomized treatment expansion – in jurisdictions where the clinical trial has obtained approval from health authorities[2]. Part 1 data will be presented to the United States (U.S.) Food and Drug Administration (FDA) to seek an Investigational New Drug (IND) amendment to progress Part 2 in the U.S.

Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, Salt Lake City, and ProstACT Global Principal Investigator and Steering Committee member, commented, "These results reinforce the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC, including ARPIs such as enzalutamide or abiraterone, or docetaxel. Hematologic events align with those typically seen in this patient population and therapeutic class, and these cases resolved quickly. The dosimetry profile, along with the low-grade nature of non-hematologic adverse events, further supports the tolerability profile of this investigational therapy."

[1] National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for Prostate Cancer V3.2026; Narayan et al. *Clin Genitourin Cancer.* 2024.

David N. Cade, MD, Group Chief Medical Officer, Telix added, “Despite advances in clinical practice, men with advanced prostate cancer still need improved first and second line treatment options. These results build on prior findings and highlight the potential for TLX591-Tx in combination with contemporary standard of care, to become a new first-line option for patients facing this aggressive disease. We are encouraged by the data and look forward to engaging with the FDA at the earliest opportunity, while continuing to advance enrollment in Part 2 in regions where clinical trial initiation has already been approved.”

Summary results

ProstACT Global Part 1 dosed 36 patients, allocated across 3 cohorts:

- Cohort 1 (11 patients): TLX591-Tx + enzalutamide.
- Cohort 2 (11 patients): TLX591-Tx + abiraterone.
- Cohort 3 (14 patients): TLX591-Tx followed by docetaxel.

Safety and tolerability

- An acceptable safety profile was observed across combination cohorts and tolerability of TLX591-Tx was consistent with prior studies.
- All 36 patients received both doses of TLX591-Tx per protocol, no new safety signals were observed.
- Almost all treatment-emergent non-hematologic events were Grade 1 or Grade 2. The most prevalent were fatigue (53%), nausea (28%) and dry mouth (25%).
- Hematologic events were transient and manageable.
- Grade 3 thrombocytopenia (14%) and neutropenia (22%), and Grade 4 thrombocytopenia (31%) and neutropenia (25%) events were in line with the profile expected for this class of therapy and extent of disease.

Dosimetry and biodistribution

- Radiation exposure to key organs was well below established safety limits[3].
- Limited dose to salivary glands and kidneys.
- Lesion dosimetry demonstrated uptake across tumor sites and across all cohorts.
- Pharmacokinetics demonstrated sustained activity at 15 days, corroborated by imaging which demonstrated prolonged tumor retention.
- No evidence of drug-drug interactions impacting TLX591-Tx targeting, distribution or clearance.

About ProstACT Global

ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 36 patients (complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a ^{68}Ga-PSMA-11 PET[4] imaging agent (such as Illuccix®, kit for the preparation of gallium-68 (^{68}Ga) gozetotide injection, or Gozellix®, kit for the preparation of gallium-68 (^{68}Ga) gozetotide injection) following prior treatment with one ARPI.

The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small molecule radioligand therapies (RLT). In contrast to these therapies[5], collective long-term follow-up of patients administered with TLX591-Tx has not observed significant acute or delayed kidney toxicity, as the agent is primarily cleared through the liver, a comparatively

[2] Part 2 is enrolling in Australia, New Zealand, and Canada, and has also received regulatory approval to commence in China, Singapore, South Korea, Türkiye, and the United Kingdom.
[3] Wahl et al. *J Nucl Med.* 2021; Emami et al. *Int J Radiat Oncol Biol Phys.* 1991.
[4] Positron emission tomography.

radioresistant organ, instead of the kidneys[6]. Due to its large molecular weight, TLX591-Tx also demonstrates minimal salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs[7].

Additional information on the Phase 3 ProstACT Global study can be found at: https://telixpharma.com/prostact/

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, with the goal to address significant unmet medical needs in oncology and rare diseases. With international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is headquartered in Melbourne, Australia. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Telix's Precision Medicine franchise includes Illuccix®, approved in multiple markets globally, and Gozellix®, approved by the U.S. FDA[8]. TLX591-Tx has not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson
SVP Investor Relations and Corporate Communications
kyahn.williamson@telixpharma.com

Telix Investor Relations (Australia)

Ms. Charlene Jaw
Associate Director Investor Relations
charlene.jaw@telixpharma.com

Telix Investor Relations (U.S.)

Ms. Annie Kasparian
Director Investor Relations and Corporate Communications
annie.kasparian@telixpharma.com

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

[5] Tagawa et al. *Curr Oncol Rep.* 2021; Steinhelfer et al. *J Nucl Med.* 2024.
[6] Tagawa et al. *Cancer.* 2019.
[7] Pepin et al. *Pract Radiat Oncol.* 2025.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

[8] Telix ASX disclosure March 21, 2025.

Telix Therapeutics

ProstACT Global

TLX591-Tx
ProstACT Global Phase 3 study (NCT06520345)

Part 1 results: Safety and dosimetry

March 10, 2026

ASX: TLX | NASDAQ: TLX

Forward looking statements

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Ex Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitte information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of nev otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or o

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 199 or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plar negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and ot achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward- assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the f correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, p research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, inclu approvals for Telix's product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they hav reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's finan anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix' performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differenc forward-looking statements.

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other da and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix's future necessarily subject to a high degree of uncertainty and risk.

Telix's first generation PSMA-PET imaging product, gallium-68 (^{68}Ga) gozetotide injection (also known as ^{68}Ga PSMA-11 and marketed under the (kit for the preparation of gallium-68 (^{68}Ga) gozetotide injection) has been approved by the U.S. FDA. Telix's osteomyelitis (bone infection) imagi Scintimun®) is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive anc attained a Conformité Européenne (CE) Mark for use in the EEA. Registrations vary country to country. Refer to your local approved label or regula

No other Telix drug or device has received marketing authorization in any jurisdiction. Any other Telix drug or device that is discussed in this pre and not approved by any regulatory authority. The efficacy or safety profile of any unapproved drug or device has not been determined by any re subject to final regulatory approval.

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owner intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third

Telix
Therapeutics

Presenters

Dr. Christian Behrenbruch

Managing Director and
Group CEO

David N. Cade, MD

Telix Group Chief
Medical Officer

Telix

*Independent expert speaker, not an employee of Telix.
Views are speaker's own.

Telix Therapeutics

ProstACT Global

Introductory remarks

Telix

ProstACT Global Phase 3 (Part 1 Lead-in)

Primary and secondary endpoints: Safety and dosimetry

- **Study objectives met:** Confirmed safety, pharmacokinetics, dosimetry ac
- **No new safety signals:** Hematologic events transient and manageable
- **Tolerability profile** supported by dosimetry and low-grade non-hematolog
- Lesion dosimetry indicates no difference in **absorbed dose profile** across
- **No adverse drug-drug interactions** observed in TLX591-Tx combination

Demonstrates feasibility of integrating TLX591-Tx with contemp

Telix Therapeutics

1. Source: ProstACT Global Part 1 data on file.

TLX591-Tx is a novel therapy candidate fo

Differentiated radiopharmaceutical using an antibody (mA

TLX591-Tx:
Lutetium (^{177}Lu) rosopatamab tetraxetan



Radio antibody-drug conjugate (rADC) key unmet needs[2-5]

1. **Patient friendly two-dose regimen:** and ease of integration with standard
2. **Safety and tolerability profile:** Low and kidneys, transient and manageab
3. **Internalization and prolonged reter** to the tumor, potentially maximizing c
4. **Supply, access, and radiation prote** from lower administered activity (76 n

Differences described are not derived from head-to-head clinical studies, cross

Telix Therapeutics

1. Prostate-specific membrane antigen.
2. Sartor O, et al. Presented at: American Society of Clinical Oncology Annual Meeting 2024; TPS5115.
3. Sun M, et al. *Curr Oncol Rep*. 2021.
4. ProstACT SELECT data on file. Clinical Stu
5. Tagawa ST, et al. *Cancer*. 2019.

TLX591-Tx rADC versus 1st generation sm

Key differences underpin PSMA tumor targeting, internaliz

	rADC	1st generation RLT[5]
Radiopharmaceutical description	TLX591-Tx[1-4]	Small Molecule
Recommended dose	2 x 76 mCi (14 days apart)	6 x 200 mCi (6 weeks apart)[6]
Molecular weight (MW)	Antibody Large (mw ~150,000)	Small molecule (mw ~1,200)
Terminal half-life ($t_{1/2}$)	5.6 days	1.7 days
Off-target organ exposure	Liver, spleen	Salivary glands, kidneys, GI[7] tract, other sites
Route of excretion	Hepatobiliary (liver)	Renal (kidneys)

Differences described are not derived from head-to-head clinical studies, cross-trial comparison should be interpreted as not being definiti

Telix Therapeutics

1. Sartor O, et al. Presented at: American Society of Clinical Oncology Annual Meeting 2024; TPS5115.
2. Sun M, et al. *Curr Oncol Rep.* 2021.
3. Data on file. Telix Pharmaceuticals Limited.
4. Tagawa ST et al. *Cancer.* 2019.
5. Radio-ligand therap
6. Lu177-PSMA617. F every 6 weeks for u use.
7. Gastrointestinal.

Telix Therapeutics

ProstACT Global

Study design and patient population

Telix

ProstACT Global study design reflects gl

Allows investigator to combine TLX591-Tx with ARPI or do

Typical clinical practice following disease progression on first ARPI

Predominantly ARPI Switch[2]

Predominantly Docetaxel[3,4,5,6,7,8]



Telix Therapeutics

1. Clarivate Prostate Cancer Market Forecast, July 2025.
2. Narayan V. et al, Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor- Experienced Patients with Metastatic Castration Resistant Prostate Cancer, *Clin Genitourin Cancer*. 2024.
3. 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer.
4. 2025 ESMO Treatment Guidelines / EAU Prostate Cancer Guidelines.
5. 2025 Chinese Society of Clinical Oncology Guideline.
6. Korean Guidelines for th
7. Japanese Clinical Practi
8. Fontes et al. Treatment An Analysis of a Private
9. National Comprehensive Prostate Cancer V3.202

ProstACT Global Phase 3 current status

Part 2 approved in select jurisdictions and enrolling patier
Part 1 complete, prerequisite for progression to Part 2 in U

ProstACT™ Global

ClinicalTrials.gov ID: NCT06520345.



Telix Therapeutics

1. Data to be submitted to FDA to seek IND amendment/Part 2 clearance.
2. Metastatic castration resistant prostate cancer.
3. Safety & tolerability reported as adverse events.
4. Independent Data Monitoring Committee review, October 2025.
5. Japanese regulator has granted a patients, prior to commencing Pa
6. Radiographic progression-free su
7. Blinded independent central revie

Part 1 enrolled 36 patients each with one

All patients received two doses of TLX591-Tx

Key observations

- No treatment-related deaths
- 32 patients remain alive
- 26 patients continuing on the study



Telix Therapeutics

Part 1: Baseline demographics and prior t

Majority of patients (n=36) are 2L mCRPC

Baseline age demographics

Slightly older patient population compared to other ^{177}Lu-PSMA trials[2]

- Mean age: 75 years
- Median age: 77 years
- Age range: 59 – 88 years

Prior treatments	
Setting of 1st ARPI indication, n (%)	
mCSPC[3]	10 (28)
mCRPC 1L	26 (72)
Prior ARPI therapy, n (%)	
Abiraterone	10 (28)
Apalutamide	3 (8)
Darolutamide	6 (17)
Enzalutamide	17 (47)
Prior taxane treatment in mCSPC, n (%)	
Yes	9 (25)
No	27 (75)

Telix Therapeutics

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.
2. Morris et al. *Lancet* 2024.
3. Metastatic castration sensitive prostate cancer.
4. Prostate-specific antigen.

Telix Therapeutics

ProstACT Global

Safety

Telix

Acceptable safety profile confirmed with r

Non-hematologic events were low grade, hematologic even and manageable

Key observations

Treatment emergent adverse events (TEAE)

- Most prevalent non-hematologic adverse events were fatigue (53%), nausea (28%) and dry mouth (25%)
- Almost all TLX591-Tx related non-hematologic events were grade 1 or grade 2[2]

Hematologic events: In line with profile expected for this class of therapy

- **Grade 3** thrombocytopenia 5/36 (14%) and neutropenia 8/36 (22%) events in line with profile expected for this class of therapy; single Grade 3 anemia
- **Grade 4** thrombocytopenia 11/36 (31%) and neutropenia 9/36 (25%)

Pro

Advers Event
Non-hemato
Fatigue
Nausea
Dry mou
Diarrhe
Back pa
Headach
Hematologi
Thrombocyto
Neutrope
Anemia
WBC[3] decr
Lymphope

Telix Therapeutics

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.
2. One grade 3 dizziness was considered treatment-related.
3. White blood cell.

Hematological profile transient and consiste

Platelet counts recovered consistently in all three cohorts

TLX591-Tx (2 doses at 76 mCi each)



Telix Therapeutics

1. G1 platelets 75,000/µL to 150,000 /µL

Telix Therapeutics

ProstACT Global

Dosimetry

Telix

Pharmacokinetic profile driven by TLX591

Demonstrates sustained activity, consistent across cohort

Blood radioactivity
Concentrations-Time Profile



Lesion activity
Concentrations-Time profile



Abiraterone[2,3] Docetaxel[2,3] Enzalutamide[2,3]

Telix Therapeutics

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.
2. Lesion and blood activity concentrations were measured following the first TLX591-Tx dose (2.8 GBq; ~76 mCi).
3. Number of patients in abiraterone cohort (n = 11), Docetaxel (n = 13), Enzalutamide (n = 10).

PK and lesion activity an
Demographic and safety
patient numbers reflect d

Organ radiation exposure is well below es

Low radiation to salivary glands and kidneys supports tole



Telix Therapeutics

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals. Organ mean absorbed dose reported in (n = 33) patients. Red Marrow dose determined from blood-based assay, 1.03 ± 0.31 Gy for 2 cycles of 76 mCi.
2. Wahl RL, Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns, *J Nucl Med*
3. Emami et al. Tolerance of *Phys.* 1991.

Lesion dosimetry confirmed TLX591-Tx u

Meaningful absorbed dose across lesion locations and co

Tumor dose (Gy) after the administration of TLX591-Tx in 2 doses o

Tumor Sites	Mean	Median	Min
All lesions (n=132)	4.83	2.84	0.28
Bone (n=122)	5.00	2.92	0.28
Lymphatic nodes (n=8)	2.01	2.15	1.02
Soft tissue (n=2)	5.73	5.73	3.27

The mean tumor volume by site was 13.47 ± 16.22 mL for
for lymphatic tissue and 9.87 ± 0.15 mL for soft

Telix Therapeutics

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.

Patient case: TLX591-Tx plus abiraterone

64-year-old patient with metastatic disease in lymph nodes

SPECT TLX591-Tx biodistribution: Single dose **Distributio**



TLX591-Tx seen in the vascular space and liver

met

Administration of one dose of TLX591-Tx

BASELINE PET MAR 25	4 hours	24 hours	96 hours	

Telix Therapeutics

1. Subcarinal, right upper para-tracheal, abdominal, pelvic lymph nodes.
2. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.

Patient case: TLX591-Tx sequenced with

83-year-old patient with bony metastatic lesions[1]

SPECT TLX591-Tx biodistribution: Single dose Distributio



TLX591-Tx seen in the vascular space and liver

met

Administration of one dose of TLX591-Tx

BASELINE PET MAR 25	4 hours	24 hours	96 hours	

Telix Therapeutics

1. Thoracic vertebrae, ribs.
2. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.

Telix Therapeutics | ProstACT Global

Summary

Telix

Summary: ProstACT Global Part 1

TLX591-Tx plus standard of care has acceptable safety an

- **Acceptable and manageable safety and tolerability** demonstrated across combination cohorts, no new safety signals or adverse drug-drug interactions
- **Low radiation exposure to salivary glands and kidneys** support acceptable tolerability profile
- **Pharmacokinetics supports sustained activity at 15 days**, imaging shows prolonged tumor retention
- **Patient friendly two dose regimen** supports compliance to treatment and ease of integration with standard of care (SOC)

Telix Therapeutics

1. ProstACT Global Part 1 data on file. Telix Pharmaceuticals.

Investor Relations Contacts:

Kyahn Williamson (Global)
SVP Investor Relations and Corporate Communications
kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)
Ms. Annie Kasparian
Director Investor Relations and Corporate Communications
annie.kasparian@telixpharma.com

Telix Investor Relations (Australia)
Ms. Charlene Jaw
Associate Director Investor Relations
charlene.jaw@telixpharma.com